There is increasing evidence to suggest that the cannabinoid system is a crucial mechanism in the regulation of feeding and metabolism. It is against this background that a cannabinoid antagonist, rimonabant, is about to come onto the market for the treatment of obesity. Moreover, in addition to weight-loss effect, this drug has a beneficial effect on the so-called metabolic syndrome, with changes in the lipid and glucidic metabolism not observed for other anti-obesity drugs currently available. We present a review of current knowledge in this field and data from our own studies: genetic studies of this system in eating disorders and in obesity and studies of localization of cannabinoid receptors at sites related to feeding. These studies support a state of cannabinoid hyperactivity in obesity; furthermore, such hyperactivity can constitute a prognostic factor. (English) [ABSTRACT FROM AUTHOR]
CITATION STYLE
Arias Horcajadas, F. (2008). Sistema cannabinoide y regulación de la conducta alimentaria. Adicciones, 20(2), 171. https://doi.org/10.20882/adicciones.281
Mendeley helps you to discover research relevant for your work.